Annals of Oncology 13:1693-1694, 2002
© 2002 European Society for Medical Oncology
News |
President Bush nominates top White House aide as FDA chief
| The first 150 words of the full text of this article appear below. |
The long search for a new commissioner of the US Food and Drug Administration (FDA) ended in early October 2002. However, the appointment of Dr Mark B. McClellan (with a medical degree from Harvard and a PhD in economics from the Massachusetts Institute of Technology), the President’s top health-policy adviser, has still to be confirmed. The previous commissioner, Jane Henney, who was appointed by the Clinton administration, had approved the ‘morning-after pill’, and, even if she had wished to stay on, was therefore unacceptable to the conservative anti-abortion Bush administration. With an annual budget of US$1.7 billion and over 10 000 employees, the FDA has approval authority in the USA over all pharmaceutical drugs, medical devices, and their advertising and labelling, 80% of the food supply, and veterinary feed and drugs. The FDA is regularly under attack, from various quarters, either as an impediment to pharmaceutical innovation or as a compliant
An alternative approach to the Hahnemann theory of infinitesimal dilution
Elderly patients are being left out of critical cancer research and not offered the best treatment options
President Bush gives a remarkable speech and announces an increase in cancer research funding
Nobel prize for "Physiology or Medicine" 2002: when a worm brings you under the spotlight
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Tanneberger, G. Melilli, E. Strocchi, C. Frenquelli, and Q. F. Pannuti Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents? Ann. Onc., May 1, 2004; 15(5): 839 - 840. [Full Text] [PDF]
|
|